CDXC - クロマデックス (ChromaDex Corporation) クロマデックス

 CDXCのチャート


 CDXCの企業情報

symbol CDXC
会社名 ChromaDex Corp (クロマデックス)
分野(sector) Consumer Durables   耐久消費財
産業(industry) Specialty Chemicals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Chromadex Corporation and its subsidiaries ChromaDex Inc. ChromaDex Analytics Inc. and Spherix Consulting Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover acquire develop and commercialize ingredient technologies that address the dietary supplement food beverage skin care and pharmaceutical markets. The Company operates through three segments: Ingredients which develops supplies and commercializes ingredient technologies; Core standards and contract services which supplies phytochemical reference standards which are small quantities of plant-based compounds used to research an array of attributes reference materials and related contract services and Scientific and regulatory consulting which provides scientific and regulatory consulting to the clients in the food supplement and pharmaceutical industries to manage health and regulatory risks.   クロマデックスは米国の天然成分医薬品企業。主に、植物化学成分(ファイトケミカル)を利用した医薬品の研究開発・商業化に従事する。食品飲料、栄養補助食品医薬品、動物用医薬品、化粧品などの業界にソリュ―ションを提供する。同社製品には「ProC3G」、「PURENERGY」、「NIAGEN」を含む。本社はカリフォルニア州。   ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®.
本社所在地 10005 Muirlands Blvd. Suite G Irvine CA 92618 USA
代表者氏名 Robert N. Fried ロバート・N・フライド
代表者役職名 President Chief Executive Officer Chief Operating Officer Chief Strategy Officer Director
電話番号 +1 949-419-0288
設立年月日 38899
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 74人
url www.chromadex.com
nasdaq_url https://www.nasdaq.com/symbol/cdxc
adr_tso
EBITDA EBITDA(百万ドル) -27.54546
終値(lastsale) 3.9501
時価総額(marketcap) 217474473.7935
時価総額 時価総額(百万ドル) 200.95230
売上高 売上高(百万ドル) 27.98553
企業価値(EV) 企業価値(EV)(百万ドル) 167.97330
当期純利益 当期純利益(百万ドル) -28.53611
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Chromadex Corp revenues increased 89% to $14.4M. Net loss before extraordinary items increased from $4.5M to $16.5M. Revenues reflect Consumer Products Segments increase from $14K to $6.8M Ingredients Segments increase of 3% to $5.2M. Higher net loss reflects Other segment loss increase from $5M to $13.4M Consumer Products Segments loss totaling $3.7M vs. income of $2K Core Standards.

 CDXCのテクニカル分析


 CDXCのニュース

   ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021  2021/07/20 10:33:00 Business Wire
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results
   Increasing Demand of D-Tagatose Market by 2027 | Nunaturals, Damhert Nutrition, ChromaDex  2021/07/16 10:47:21 Tramways Monthly
D-Tagatose Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained []
   ChromaDex rises after NIAGEN-component shows promise in COVID-19 trial  2021/06/28 18:06:46 Seeking Alpha
   ChromaDex launches NAD+ booster Tru Niagen across Walmart stores in US  2021/06/27 18:13:45 Business News Today
ChromaDex, a California-based dietary supplement and food ingredient company, has launched Tru Niagen, its flagship consumer product, in 3,800 Walmart stores across the US. Tru Niagen is a form of vitamin B3 which is known for elevating nicotinamide adenine dinucleotide (NAD+), which is important in cellular energy metabolism and energy production. Apart from that, Tru [] The post ChromaDex launches NAD+ booster Tru Niagen across Walmart stores in US appeared first on Business News Today .
   Supplements company ChromaDex drops after new short call from J Capital Research  2021/06/24 11:16:09 Seeking Alpha
   ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021  2021/07/20 10:33:00 Business Wire
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., August 3, 2021 at 4:30 p.m. ET to discuss its financial results
   Increasing Demand of D-Tagatose Market by 2027 | Nunaturals, Damhert Nutrition, ChromaDex  2021/07/16 10:47:21 Tramways Monthly
D-Tagatose Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained []
   ChromaDex rises after NIAGEN-component shows promise in COVID-19 trial  2021/06/28 18:06:46 Seeking Alpha
   ChromaDex launches NAD+ booster Tru Niagen across Walmart stores in US  2021/06/27 18:13:45 Business News Today
ChromaDex, a California-based dietary supplement and food ingredient company, has launched Tru Niagen, its flagship consumer product, in 3,800 Walmart stores across the US. Tru Niagen is a form of vitamin B3 which is known for elevating nicotinamide adenine dinucleotide (NAD+), which is important in cellular energy metabolism and energy production. Apart from that, Tru [] The post ChromaDex launches NAD+ booster Tru Niagen across Walmart stores in US appeared first on Business News Today .
   Supplements company ChromaDex drops after new short call from J Capital Research  2021/06/24 11:16:09 Seeking Alpha
   ChromaDex to Present at the Zooming with LD Virtual Investor Conference  2021/03/18 10:33:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference. The ChromaDex management team is scheduled to present on Thursday, March 25, 2021 at 12:30 p.m. Eastern Time (9:30 a.m. Pacific Time). The presentation will be webcast live via the link below on the investor relations section of the Company’s website at www.chroma
   ChromaDex (NASDAQ:CDXC) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS  2021/03/12 17:06:42 Transcript Daily
ChromaDex (NASDAQ:CDXC) posted its earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01, MarketWatch Earnings reports. ChromaDex had a negative return on equity of 100.14% and a negative net margin of 39.86%. NASDAQ:CDXC opened at $11.31 on Friday. The firm has a […]
   ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference  2021/03/09 11:32:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #HealthyAging--ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:50pm ET (12:50pm PT). A webcast of the presentation will be posted under the investor relations section of ChromaDex’s website at www.chromadex.com. A replay of the presentation will be available following the event. Management will also be participating in virtual one-on-one meetings on March 16
   Why ChromaDex Shares Spiked 111% Today  2021/02/26 02:57:46 Benzinga
Chromadex Corp (NASDAQ: CDXC ) shares jumped 111% in the regular and after-hours sessions today. What Happened: The price movement on Thursday was accompanied by intense trading with volumes of 116.67 million. The average volume for ChromaDex shares is 523,511. While there were no immediate triggers for share movement on Thursday, the bioscience company announced results from a Phase 3 study that examined its … Full story available on Benzinga.com
   ChromaDex Announces $25 Million Private Placement of Common Stock  2021/02/22 11:30:00 Business Wire
ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common st

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 クロマデックス CDXC ChromaDex Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)